DA Davidson initiated coverage on USANA with a new price target
$USNA
Medicinal Chemicals and Botanical Products
Health Care
DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2023 | Buy | Sidoti | |
| 7/7/2022 | $78.00 → $53.00 | Hold → Underperform | Jefferies |
| 4/14/2022 | $86.00 | Neutral | DA Davidson |
USANA athletes from eight national teams and 12 winter sports participated in the games SALT LAKE CITY, March 3, 2026 /PRNewswire/ -- USANA Health Sciences, Inc. (NYSE:USNA) congratulates the 190 USANA-sponsored athletes* who competed at the 2026 Winter Olympic Games, earning a total of 28 medals across 12 winter sports while representing eight national teams from four countries. US Ski & Snowboard led USANA-partnered organizations with 17 medals. USANA ambassador Alex Ferreira captured his first Olympic Gold medal in men's freeski halfpipe with a decisive final run.USANA athlet
USANA Health Sciences, Inc. (NYSE:USNA) today announced that the Company will participate in the following upcoming conferences: Sidoti Small-Cap Virtual Conference Dates: March 18-19, 2026 Format: Fireside chat and one-on-one meetings 38th Annual ROTH Conference Date: March 23, 2026 Location: Dana Point, CA Format: One-on-one meetings A live webcast of the fireside chat at the Sidoti Small-Cap Virtual Conference will be available in the ‘News/Events' section of the Company's website at ir.usana.com. The webcast will be archived and available on the website shortly after the event. About USANA USANA develops and manufactures high-quality nutritional supplements, functional foods
SALT LAKE CITY, March 2, 2026 /CNW/ -- As businesses navigate accelerating change and increased market pressure, USANA Health Sciences (NYSE:USNA) Chairman & CEO Kevin Guest is spotlighting a powerful leadership tool during National Reading Month: disciplined, intentional reading. National Reading Month, observed in March to promote literacy and lifelong learning, often emphasizes youth engagement. Guest believes its value extends far beyond the classroom and into the executive suite."Reading stretches your thinking. It challenges assumptions, builds clarity, and sharpens your a
144 - USANA HEALTH SCIENCES INC (0000896264) (Subject)
8-K/A - USANA HEALTH SCIENCES INC (0000896264) (Filer)
SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
Sidoti initiated coverage of USANA with a rating of Buy
Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously
DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th
NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c
SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results Q4 2025 Q4 2024 FY 2025 FY 2024 Net sales $226.2 $213.6 $925.3 $854.5 Net (loss) earnings* $-1.8 $4.5 $10.8 $42.0 Diluted EPS $-0.10 $0.23 $0.58 $2.19 Adjusted diluted EPS(1) $0.60 $0.64 $1.93 $2.59 Adjusted EBITDA(2) $27.3
USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)